Therefore, our understanding of how ErbB2 cooperates with other oncogenic pathways in context of ErbB2 targeted therapies is critical for improvement of therapeutic outcomes in these high risk breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.